Default: Cancer Chemotherapy and Pharmacology

ISSN: 0344-5704

Journal Home

Journal Guideline

Cancer Chemotherapy and Pharmacology Q1 Unclaimed

Springer Verlag Germany
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Chemotherapy and Pharmacology is a journal indexed in SJR in Pharmacology and Oncology with an H index of 111. It has a price of 3060 €. It has an SJR impact factor of 1,112 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,112.

Cancer Chemotherapy and Pharmacology focuses its scope in these topics and keywords: cell, human, patients, kinase, breast, highdose, etoposide, combination, correlation, sensitivity, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Metrics

Cancer Chemotherapy and Pharmacology

1,112

SJR Impact factor

111

H Index

198

Total Docs (Last Year)

747

Total Docs (3 years)

6622

Total Refs

2309

Total Cites (3 years)

733

Citable Docs (3 years)

2,93

Cites/Doc (2 years)

33,44

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


cell, human, patients, kinase, breast, highdose, etoposide, combination, correlation, sensitivity, temozolomide, therapy, pathway, phase, solid, study, cancer, cells, ovarian, oral,



Best articles by citations

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

View more

Peptides designed from molecular modeling studies of the ras -p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth

View more

Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors

View more

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

View more

Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

View more

Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy

View more

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

View more

Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil

View more

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

View more

Structural development of synthetic retinoids and thalidomide-related molecules

View more

Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay

View more

Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents

View more
SHOW MORE ARTICLES

Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo

View more

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

View more

Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule

View more

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

View more

Granisetron: is there a dose?response effect on nausea and vomiting?

View more

BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR

View more

Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates

View more

An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU

View more

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

View more

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

View more

Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer

View more

Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers

View more

FAQS